Diabetes mellitus as an economic problem in Russian Federation

Objective.To estimate annual expenditures attributed to diabetes mellitus (DM) per patient in Russia based on data from epidemiologic studies and to analyse DM cost drivers.Methods.The expenditures per diabetic patient were calculated as the sum of medical costs (outpatient and emergency room visits...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Ivanovich Dedov, Vitaliy Vladimirovich Omelyanovskiy, Marina Vladimirovna Shestakova, Maria Vladimirovna Avksentieva, Viktoria Igorevna Ignatieva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	diabetes mellitus economic burden cost drivers Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/8d502dd23559480ebbdd15bdd0a45cfb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d502dd23559480ebbdd15bdd0a45cfb
record_format	dspace
spelling	oai:doaj.org-article:8d502dd23559480ebbdd15bdd0a45cfb2021-11-14T09:00:20ZDiabetes mellitus as an economic problem in Russian Federation2072-03512072-037810.14341/DM7784https://doaj.org/article/8d502dd23559480ebbdd15bdd0a45cfb2016-01-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7784https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Objective.To estimate annual expenditures attributed to diabetes mellitus (DM) per patient in Russia based on data from epidemiologic studies and to analyse DM cost drivers.Methods.The expenditures per diabetic patient were calculated as the sum of medical costs (outpatient and emergency room visits, inpatient care and medications provided during outpatient care), payments for sick leaves, disability pensions and gross domestic production (GDP) losses due to temporary disability (indirect costs). All data on resource consumption and productivity losses were derived from the dataset for Russia, collected from the point of view of a multicentre international study on the practice of DM treatment. Medication costs were based on registered governmental price lists (list of vital and essential drugs). Medical care costs were estimated using the approved public health care reimbursement rates. Disability payments were calculated on the basis of data published by the Russian Pension Fund and Social Security Fund. GDP losses were assessed using federal statistics.Results.The mean total annual costs per patient with DM type 1 (T1) were 81.1 thousand Russian rubles (RUR) and those per patient with DM type 2 (T2) were 70.8 thousand RUR. Although most patients with DMT2 were >60 years, approximately 25% of costs were nonmedical and caused by productivity losses; for patients with DM type 1(T1), this proportion was 35%. The medical cost structure differed depending on the type of diabetes. In T1, the main component was attributed to DM treatment; in DMT2, almost half of medical costs were due to DM complications. Medication costs accounted for 69% and inpatient care accounted for only 22% of medical costs in DMT1. For DMT2, the proportion spent on inpatient care (43%) was almost equal to medication costs (46%). Mean expenditures per patient with DM complications were higher; in the case of DMT2, the presence of complications increased the costs by 3 times. Mean medical costs were higher for patients not reaching the target level of Hb1Ac than those reaching it, despite age or the presence of complications. The results of regression analysis showed that the strongest predictors of costs growth were the number of admissions, presence of complications and insulin treatment. It was also demonstrated that the mean medical cost per patient with uncomplicated DM T2 on insulin therapy was 38.5 thousand RUR, which was comparable to the cost per patient with complications, receiving other glucose-lowering treatment (37.0 thousand RUR).Conclusion.Costs for patients with DM complications are considerably higher than those for patients without complications. Therefore, the key point in controlling the growth of the DM economic burden is to minimise and/or prevent the development of DM complications, which could be achieved by timely DM diagnosis and appropriate glucose-lowering therapy.Ivan Ivanovich DedovVitaliy Vladimirovich OmelyanovskiyMarina Vladimirovna ShestakovaMaria Vladimirovna AvksentievaViktoria Igorevna IgnatievaEndocrinology Research Centrearticlediabetes mellituseconomic burdencost driversNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 1, Pp 30-43 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus economic burden cost drivers Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus economic burden cost drivers Nutritional diseases. Deficiency diseases RC620-627 Ivan Ivanovich Dedov Vitaliy Vladimirovich Omelyanovskiy Marina Vladimirovna Shestakova Maria Vladimirovna Avksentieva Viktoria Igorevna Ignatieva Diabetes mellitus as an economic problem in Russian Federation
description	Objective.To estimate annual expenditures attributed to diabetes mellitus (DM) per patient in Russia based on data from epidemiologic studies and to analyse DM cost drivers.Methods.The expenditures per diabetic patient were calculated as the sum of medical costs (outpatient and emergency room visits, inpatient care and medications provided during outpatient care), payments for sick leaves, disability pensions and gross domestic production (GDP) losses due to temporary disability (indirect costs). All data on resource consumption and productivity losses were derived from the dataset for Russia, collected from the point of view of a multicentre international study on the practice of DM treatment. Medication costs were based on registered governmental price lists (list of vital and essential drugs). Medical care costs were estimated using the approved public health care reimbursement rates. Disability payments were calculated on the basis of data published by the Russian Pension Fund and Social Security Fund. GDP losses were assessed using federal statistics.Results.The mean total annual costs per patient with DM type 1 (T1) were 81.1 thousand Russian rubles (RUR) and those per patient with DM type 2 (T2) were 70.8 thousand RUR. Although most patients with DMT2 were >60 years, approximately 25% of costs were nonmedical and caused by productivity losses; for patients with DM type 1(T1), this proportion was 35%. The medical cost structure differed depending on the type of diabetes. In T1, the main component was attributed to DM treatment; in DMT2, almost half of medical costs were due to DM complications. Medication costs accounted for 69% and inpatient care accounted for only 22% of medical costs in DMT1. For DMT2, the proportion spent on inpatient care (43%) was almost equal to medication costs (46%). Mean expenditures per patient with DM complications were higher; in the case of DMT2, the presence of complications increased the costs by 3 times. Mean medical costs were higher for patients not reaching the target level of Hb1Ac than those reaching it, despite age or the presence of complications. The results of regression analysis showed that the strongest predictors of costs growth were the number of admissions, presence of complications and insulin treatment. It was also demonstrated that the mean medical cost per patient with uncomplicated DM T2 on insulin therapy was 38.5 thousand RUR, which was comparable to the cost per patient with complications, receiving other glucose-lowering treatment (37.0 thousand RUR).Conclusion.Costs for patients with DM complications are considerably higher than those for patients without complications. Therefore, the key point in controlling the growth of the DM economic burden is to minimise and/or prevent the development of DM complications, which could be achieved by timely DM diagnosis and appropriate glucose-lowering therapy.
format	article
author	Ivan Ivanovich Dedov Vitaliy Vladimirovich Omelyanovskiy Marina Vladimirovna Shestakova Maria Vladimirovna Avksentieva Viktoria Igorevna Ignatieva
author_facet	Ivan Ivanovich Dedov Vitaliy Vladimirovich Omelyanovskiy Marina Vladimirovna Shestakova Maria Vladimirovna Avksentieva Viktoria Igorevna Ignatieva
author_sort	Ivan Ivanovich Dedov
title	Diabetes mellitus as an economic problem in Russian Federation
title_short	Diabetes mellitus as an economic problem in Russian Federation
title_full	Diabetes mellitus as an economic problem in Russian Federation
title_fullStr	Diabetes mellitus as an economic problem in Russian Federation
title_full_unstemmed	Diabetes mellitus as an economic problem in Russian Federation
title_sort	diabetes mellitus as an economic problem in russian federation
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/8d502dd23559480ebbdd15bdd0a45cfb
work_keys_str_mv	AT ivanivanovichdedov diabetesmellitusasaneconomicprobleminrussianfederation AT vitaliyvladimirovichomelyanovskiy diabetesmellitusasaneconomicprobleminrussianfederation AT marinavladimirovnashestakova diabetesmellitusasaneconomicprobleminrussianfederation AT mariavladimirovnaavksentieva diabetesmellitusasaneconomicprobleminrussianfederation AT viktoriaigorevnaignatieva diabetesmellitusasaneconomicprobleminrussianfederation
_version_	1718429543635615744

Diabetes mellitus as an economic problem in Russian Federation

Ejemplares similares